Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC By Ogkologos - September 9, 2025 598 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the A-BRAVE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly with Chemotherapy September 5, 2024 Bringing a Piece of Home to the Hospital April 4, 2023 The incredible value of going public November 22, 2021 Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus... February 24, 2025 Load more HOT NEWS COVID-19 in people with cancer – what we know so far FDA Grants Accelerated Approval to Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial... Cancer in My Community: Developing Pediatric Palliative and Supportive Care in... Woman Has Unnecessary Double Mastectomy and Narrowly Avoids Hysterectomy After Bad...
